Related Experiment Video
Updated: Sep 26, 2025
Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues
Published on: August 23, 2024
Sensitive Measurement of Minimal Residual Disease in Blood by HAT-PCR
Sue Latham1, Elizabeth Hughes1, Bradley Budgen1
1College of Medicine and Public Health, Flinders University, Adelaide, SA, Australia.
Abstract:
PCR is widely used to measure minimal residual disease (MRD) in lymphoid neoplasms, but its sensitivity is limited. High Adenine/Thymine PCR and High Annealing Temperature PCR (HAT-PCR) is a modified PCR designed to minimize nonspecificity and hence increase sensitivity. It was evaluated in the laboratory and the clinic, using samples from 58 patients. Of these patients, 57 were adolescents or young adults who were participating in the Australasian Leukemia and Lymphoma Group ALL06 trial in which MRD was measured in blood principally by HAT-PCR and in marrow by conventional PCR. HAT-PCR produced significantly less nonspecificity than conventional PCR, and its limit of detection was <10-6 in 90% of patients. In 196 samples, an excellent correlation was found between blood and marrow MRD. Variable partitioning of leukemic cells between blood and marrow was observed. Measurement of MRD in blood by HAT-PCR was noninferior to measurement of MRD in marrow by conventional PCR, in terms of both detecting disease and predicting clinical outcome. At a median follow-up of 3 years and for MRD levels in blood at the end of consolidation treatment, an MRD level of >10-4 cells/L significantly predicted relapse and mortality, whereas undetectable MRD significantly predicted relapse-free survival and overall survival. HAT-PCR is a simple, quick, cheap and sensitive method for measurement of MRD, and its adoption for MRD in blood may be clinically useful.
Insights
High Adenine/Thymine PCR and High Annealing Temperature PCR (HAT-PCR) improves minimal residual disease (MRD) detection in lymphoid neoplasms. This sensitive HAT-PCR method in blood is comparable to conventional PCR in marrow for predicting patient outcomes.
Area of Science:
- Hematology
- Molecular Biology
- Oncology
Background:
- Polymerase Chain Reaction (PCR) is crucial for minimal residual disease (MRD) assessment in lymphoid neoplasms.
- Conventional PCR methods face limitations in sensitivity due to nonspecificity.
Purpose of the Study:
- To evaluate the sensitivity and clinical utility of High Adenine/Thymine PCR and High Annealing Temperature PCR (HAT-PCR) for MRD measurement.
- To compare HAT-PCR in blood with conventional PCR in marrow for detecting MRD in lymphoid neoplasms.
Main Methods:
- HAT-PCR, a modified PCR technique, was developed to enhance specificity and sensitivity.
- Laboratory and clinical evaluation involved samples from 58 patients, primarily adolescents and young adults in the ALL06 trial.
- MRD levels were measured in blood using HAT-PCR and in marrow using conventional PCR.
Main Results:
- HAT-PCR demonstrated significantly reduced nonspecificity compared to conventional PCR.
- The limit of detection for HAT-PCR was <10-6 in 90% of patients.
- Excellent correlation between blood and marrow MRD was observed (196 samples); HAT-PCR in blood was noninferior to conventional PCR in marrow for disease detection and outcome prediction.
Conclusions:
- HAT-PCR is a simple, rapid, cost-effective, and highly sensitive method for MRD measurement.
- Utilizing HAT-PCR for MRD assessment in blood offers clinical utility and may be advantageous.
- High MRD levels (>10-4 cells/L) in blood predicted relapse and mortality, while undetectable MRD predicted favorable survival.
More Related Videos
09:57Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
Published on: March 5, 2018
09:16Detection of a CDH1 Rare Transcript Variant in Fresh-frozen Gastric Cancer Tissues by Chip-based Digital PCR
Published on: February 5, 2018
